Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 250.00 Million |
| USD 383.67 Million | |
| % | |
|
Global Breast Lesion Guidance Systems Market, By Type (Wire, Radioisotope, Magnetic, Electromagnetic Localization), Usage (Breast Biopsy, Lumpectomy), End User Preference Survey (Selection Criteria, Replacement Trend) – Industry Trends and Forecast to 2029
The global breast lesion guidance system market is expected to witness significant growth during the forecast period. One-third of breast cancers diagnosed each year worldwide are subtle, and this level rises as screening programs become more prevalent and more advanced modalities such as MRI detect more clinically potential lesions. It is a safe and accurate non-surgical method for diagnosing suspicious abnormal findings in breast images and is essential for proper decision making, including treatment planning.
Data Bridge Market Research analyses a growth rate in the Global breast lesion guidance systems market in the forecast period 2022-2029. The expected CAGR of Global breast lesion guidance systems market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 250 million in 2021, and it would grow upto USD 383.67 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Wire, Radioisotope (ROLL,RSL), Magnetic, Electromagnetic Localization), Usage (Breast Biopsy,Lumpectomy), End User Preference Survey (Selection Criteria, Replacement Trend)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
BD (US), C.R. Bard, Inc. (US), Devicor Medical Products Inc. (US), and Hologic Inc. (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), Matek Medikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada), Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeo srl (Italy), and Medax Medical Devices (Italy)
|
|
Market Opportunities
|
|
Market Definition
Cardiac disease is often overlooked on cardiac CT. However, the soft tissue function of the multi-detector CT is sufficient for reliable diagnosis. Breast lesions or injuries are abnormal changes in breast tissue caused by the disease or injury, and breast lesion locating procedures are used to detect, diagnose, and treat diseases or injuries associated with breast tissue. Appropriate guidance systems will lead to the growth of the market.
Drivers
Breast cancer is among the most common diseases affecting women in developed and developing countries. According to the American Cancer Society, breast cancer is the second leading cause of cancer related deaths in women across the globe. Globally, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries, such as breast enhancement.
With age, the risk of developing breast cancer increases. With aging, pluripotent progenitor cells (a type of adult stem cell at the root of many breast cancers) increase, lining breast lactating lumen cells, and reducing the number of myoepithelial cells that function as tumor suppressors. According to the American Cancer Society, about one-eighth of invasive breast cancers occur in women under the age of 45. In contrast, women over the age of 55 develop about two-thirds of invasive breast cancers.
Opportunities
Increasing funding for R&D activities for the treatment of oncological diseases by various regulators and some state governments is also expected to boost the growth of the global laboratory development testing market.
Emerging markets such as India, China, Brazil, South Korea, Turkey, Russia and South Africa offer significant growth opportunities for key players operating in the breast lesion guidance market. The large population base of India and China in particular provide a sustainable market for medical and surgical devices as a whole. Emerging market governments are also investing heavily in the development and modernization of healthcare infrastructure. For instance, according to OECD data, China's health care costs in 2020 was $ 810.8 per person. Similarly, Brazil spent about 9.5% of its GDP on health care in 2020, according to health care and financial data. The Brazilian Ministry of Health and several non-governmental agencies have also made efforts to improve early detection in the country and promote breast cancer screening and education.
Restraints/Challenges
Breast cancer surgery and lesion locating procedures are performed by experienced professionals to achieve better results. These surgeries are considered to be at higher risk than other surgeries due to various challenges such as tumor localization, risk of removal of healthy tissue, lymphedema, and seroma. Similarly, the use of radioactive substances may increase the risk of patients developing radiation-induced cancer. Radiation exposure has several short-term and long-term side effects, usually occurring within 6 months or 1 year of exposure. The most common side effects after radiation exposure include mild pain and discomfort around the breast, skin damage, swelling and inflammation of the breast and surrounding tissues, hair loss on the flanks and breasts, and fatigue. Radiation exposure can also damage nerves in the arms, hands, and chest. To mitigate these risks, the localization procedure requires trained operators and radiologists who must go through a certification process to perform localization of breast lesions.
Regulatory authorities such as the U.S. FDA need comprehensive clinical data to demonstrate the clinical safety and efficacy of approved products. Due to the stringent regulatory requirements for product approval, market players in methods of locating breast lesions (especially radioisotope locating) are nuclear regulated by the Nuclear Regulatory Commission to ensure the safe use of radioactive seeds. You need to get approval for. This approval process is so long and capital intensive that it is difficult for small manufacturers and companies with limited budgets to compete in this market.
This breast lesion guidance systems market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the breast lesion guidance systems market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the forecast period.
The COVID19 pandemic has serious implications for the diagnostic and therapeutic procedures for all non-COVID19 diseases worldwide. This has also impacted the market for breast lesion locating methods, as the adverse effects of COVID19 on people with pandemic-related blockades and comorbidities have significantly reduced attendance at hospitals, clinics and diagnostic centres. In response to COVID 19, many countries have suspended breast screening programs. For instance, in Canada, the Netherlands, Germany, Italy, the United Kingdom and Australia, national screening programs have been completely suspended for one to six months. Therefore, while the market under study was affected by the COVID 19 pandemic, the market under study regains its potential with continued vaccination and a reduction in the number of COVID 19 cases during the forecast period.
The Global breast lesion guidance systems market is segmented on the basis of type, usage and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
Usage
End-User
The breast lesion guidance systems market is analysed and market size insights and trends are provided by country, type, usage and end-user as referenced above.
The major countries covered in the breast lesion guidance systems market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the breast lesion guidance system market in recent years and is expected to show similar trends over the forecast period due to the high number of breast cancer cases, primarily coupled with strong medical infrastructure and the presence of the breast.
Asia-Pacific region is expected to grow at a significant growth rate during the forecast period of 2022 t0 2029 due to the improving healthcare infrastructure, increasing government funds on breast cancer research, and rapidly rising awareness about the importance of the early detection of breast cancer in several APAC countries.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The breast lesion guidance systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to breast lesion guidance systems market.
Key players operating in the breast lesion guidance systems market include:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.